OBJECTIVES: The research compared rectal and oral treatments with glycyrrhizic acid for trinitrobenzene sulfonic acid (TNBS)-induced colitis in rats. METHODS: Wistar rats were randomly divided into seven groups: one normal and six with colitis, including TNBS, glycyrrhizic acid (2, 10 and 50 mg/kg, rectally treated and 10 mg/kg, orally treated) and sulfasalazine (positive control, 225 mg/kg rectally treated) groups. Colitis was induced by colonic administration of TNBS in 30% ethanol. KEY FINDINGS: There were significant pathological changes in colon in TNBS-treated groups, and rectal glycyrrhizic acid significantly attenuated colitis. Myeloperoxidase, tumour necrosis factor-α and interleukin-1β of colon tissue or serum in the rectal glycyrrhizic acid groups were markedly reduced when compared with the TNBS group, and lower than in the orally treated glycyrrhizic acid group. It was further noted that, in vitro, glycyrrhizic acid (up to 100 µg/ml) inhibited interleukin-6 and elevated interleukin-10 production in lipopolysaccharide-activated macrophages, and significantly inhibited proliferation of spleen lymphocytes, suggesting the immunoregulatory function of glycyrrhizic acid. CONCLUSIONS: Rectally administered glycyrrhizic acid has significant protective effects against TNBS-induced colitis in rats, and the rectal route may be a complementary treatment for inflammatory bowel disease.
OBJECTIVES: The research compared rectal and oral treatments with glycyrrhizic acid for trinitrobenzene sulfonic acid (TNBS)-induced colitis in rats. METHODS:Wistar rats were randomly divided into seven groups: one normal and six with colitis, including TNBS, glycyrrhizic acid (2, 10 and 50 mg/kg, rectally treated and 10 mg/kg, orally treated) and sulfasalazine (positive control, 225 mg/kg rectally treated) groups. Colitis was induced by colonic administration of TNBS in 30% ethanol. KEY FINDINGS: There were significant pathological changes in colon in TNBS-treated groups, and rectal glycyrrhizic acid significantly attenuated colitis. Myeloperoxidase, tumour necrosis factor-α and interleukin-1β of colon tissue or serum in the rectal glycyrrhizic acid groups were markedly reduced when compared with the TNBS group, and lower than in the orally treated glycyrrhizic acid group. It was further noted that, in vitro, glycyrrhizic acid (up to 100 µg/ml) inhibited interleukin-6 and elevated interleukin-10 production in lipopolysaccharide-activated macrophages, and significantly inhibited proliferation of spleen lymphocytes, suggesting the immunoregulatory function of glycyrrhizic acid. CONCLUSIONS: Rectally administered glycyrrhizic acid has significant protective effects against TNBS-induced colitis in rats, and the rectal route may be a complementary treatment for inflammatory bowel disease.
Authors: Antonia Puchner; Silvia Hayer; Birgit Niederreiter; Anastasiya Hladik; Stephan Blueml; Michael Bonelli; Clemens Scheinecker; Josef Smolen; Kurt Redlich Journal: Wien Klin Wochenschr Date: 2012-01-03 Impact factor: 1.704
Authors: Sandamali A Ekanayaka; Sharon A McClellan; Ronald P Barrett; Linda D Hazlett Journal: J Ocul Pharmacol Ther Date: 2017-12-13 Impact factor: 2.671
Authors: Camila Dos Santos Leite; Gabriel Alves Bonafé; Juliana Carvalho Santos; Carlos Augusto Real Martinez; Manoela Marques Ortega; Marcelo Lima Ribeiro Journal: Int J Mol Sci Date: 2022-04-08 Impact factor: 6.208
Authors: Andrew H Wu; Li He; Wei Long; Qiuping Zhou; Shu Zhu; Ping Wang; Saijun Fan; Haichao Wang Journal: Evid Based Complement Alternat Med Date: 2015-03-02 Impact factor: 2.629
Authors: Sandamali A Ekanayaka; Sharon A McClellan; Ronald P Barrett; Shikhil Kharotia; Linda D Hazlett Journal: Invest Ophthalmol Vis Sci Date: 2016-10-01 Impact factor: 4.799